Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26495264 | 0.95 | PRMT3 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL26495342 | 0.93 | S1PR2 (0.41) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL26494037 | 0.93 | S1PR2 (0.41) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12571528 | 0.90 | PRMT3 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1231390 | 0.89 | PRMT3 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL26494024 | 0.88 | PRMT3 (0.40) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL3316611 | 0.87 | — | — | |
| SCHEMBL10540085 | 0.87 | PRMT3 (0.43) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL469832 | 0.87 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL10045279 | 0.87 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196444-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3805198-B1 | COMPOUND, SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORP (JP) | 2023-09-20 | — | — | EP | disclosed |
| EP-3805198-A1 | COMPOUND, SALT THEREOF AND LIPID PARTICLES | FUJIFILM Corporation (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-2247636-A1 | PLASTICALLY DEFORMABLE POLYURETHANE RIGID FOAMS WITH IMPROVED AIR PERMEABILITY AND USE THEREOF FOR PRODUCING AUTO ROOF LININGS | BASF SE (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009103764-A1 | PLASTICALLY DEFORMABLE POLYURETHANE RIGID FOAMS WITH IMPROVED AIR PERMEABILITY AND USE THEREOF FOR PRODUCING AUTO ROOF LININGS | BASF SE (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | PRMT3 2761/4885CARM1 3427/4885PRMT6 3265/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | PRMT3 190/4885CARM1 224/4885PRMT6 450/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | PRMT3 1375/4885CARM1 1315/4885PRMT6 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.